| ¿µ¹® | iron deficiency anemia | ÇÑ±Û | ö°áÇ̺óÇ÷ |
|---|---|---|---|
| ¼³¸í | ÀûÇ÷±¸ÀÇ ±â´ÉÀº »ê¼Ò¸¦ ¿î¹ÝÇϴµ¥ ÀÖ´Ù. ÀûÇ÷±¸ ¼Ó¿¡ »ê¼Ò¿Í °áÇÕÀ» ÇÏ¿© »ê¼Ò¸¦ ¿î¹ÝÇÏ´Â Ç÷»ö¼Ò¶ó´Â ¹°ÁúÀÌ ÀÖ´Ù. öÀº ÀÌ Ç÷»ö¼ÒÀÇ Áß¿äÇÑ ºÎºÐÀ» ÀÌ·ç´Â °ÍÀ¸·Î öÀÌ ¾øÀ¸¸é Ç÷»ö¼Ò°¡ ¸¸µé¾îÁú ¼ö°¡ ¾ø´Ù. Ç÷»ö¼Ò°¡ ¾øÀ¸¸é ¿ª½Ã ÀûÇ÷±¸µµ ¸¸µé¾îÁöÁö ¾ÊÀ¸¹Ç·Î ü³»¿¡ öÀÌ ºÎÁ·ÇÏ¸é ºóÇ÷ÀÌ »ý±ä´Ù. ÀÌ Ã¶°áÇ̼º ºóÇ÷Àº ºóÇ÷ÀÇ ¿øÀÎ Áß¿¡¼ °¡Àå ÈçÇÑ °ÍÀÌ´Ù(¾à 25%¸¦ Â÷ÁöÇÑ´Ù). öÀúÀå·®ÀÇ ÀúÇÏ-°áÇÌ, Ç÷ûö³óµµÀÇ ÀúÇÏ, Æ®¶õ½ºÆä¸°·® »ó½Â, Æ®¶õ½ºÆä¸°Æ÷ȵµÀÇ ÀúÇÏ, Ç÷»ö¼Ò³óµµ ¶Ç´Â Ç츶ÅäÅ©¸®Æ®ÀÇ ÀúÇÏ, Àú»ö¼Ò¼º´ëÀûÇ÷±¸¸¦ Ư¡À¸·Î ÇÏ´Â ºóÇ÷·Î¼, »ýü ³»¿¡¼ öÀÌ Àå±â¿¡ °ÉÃÄ °áÇÌµÇ¸ç ±× ¶§¹®¿¡ Ç÷»ö¼Ò »ý»ê °¨¼Ò¿¡ ÀÇÇØ ÀϾÙ. âÀÚ¿¡¼ÀÇ Ã¶Èí¼ö·® ºÎÁ·, öÀÇ ¼ö¿ä Áõ´ë(À¯¾Æ±â, »çÃá±â, ÀÓ½Å), ö¼Ò½Ç°úÀ×(ÃâÇ÷)¿¡ ÀÇÇØ ÀϾ¸ç, ƯÈ÷ »çÃá±â¿¡¼ Æó°æ±â±îÁöÀÇ ¿©¼º¿¡°Ô ¸¹´Ù. Áõ»óÀ¸·Î¼´Â ¾ó±¼Ã¢¹é, ÇǷΰ¨, ÇǺÎâ¹é, ¼ÕÅé º¯È(½ºÇ¬ ¸ð¾ç) µîÀ» ³ªÅ¸³½´Ù. ±¸° ¿µ¿ª¿¡¼´Â ÇôÀÇ Á¢ÃËÅë, ¹ßÀû, °ÇÁ¶°¨, »ïÅ´°ï¶õÀ» ¼ö¹ÝÇϸé Ç÷¯¸Ó-ºó½¼(Plummer-Vinson)ÁõÈıºÀ̶ó°í ÇÑ´Ù. Ç÷¾× ¼Ò°ßÀº Ç÷ûöÀº ÀúÇÏÇϸç, ö°áÇÕ´É·ÂÀÇ »ó½Â, Àú»ö¼Ò¼º ÀÛÀºÀûÇ÷±¸¼ºÀ» ³ªÅ¸³½´Ù. |
||
| ¿µ¹® | thyroid hormone | ÇÑ±Û | °©»ó»ùÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ±¤ÀÇÀÇ °©»ó¼±È£¸£¸óÀº Ƽ·Ï½Å(thyroxine(T4)), »ï¿äµåƼ·Î´Ñ(triiodothyronine (T3)), Ƽ·ÎÄ®½ÃÅä´Ñ(thyrocalcitonin)ÀÇ 3°¡ÁöÁß Çϳª¸¦ ¸»Çϳª ´ë°³ÀÇ °æ¿ì ÇùÀÇÀÇ ¶æÀ¸·Î »ç¿ëµÇ¸ç ÀÌ °æ¿ì Ƽ·Ï½Å°ú »ï¿äµåƼ·Î´ÑÀ» ÁöĪÇÑ´Ù. °©»ó¼± È£¸£¸óÀº °ÅÀÇ ¸ðµç ¸ö¼¼Æ÷¿¡¼ÀÇ ¹ÙÅÁÁú´ë»ç¿¡ °ü¿©ÇÏ¿© ¿¡³ÊÁö»ý¼ºÀ» Áõ°¡½ÃŰ°í ¼ºÀå ¹ßÀ°À» ÃËÁøÇÑ´Ù. À̰ÍÀº ³úÇϼöü¿¡¼ ºÐºñµÇ´Â °©»ó»ù ÀÚ±ØÈ£¸£¸ó¿¡ ÀÇÇØ ÇÕ¼º ¹× ºÐºñ°¡ ÃËÁøµÈ´Ù. ¼·ÃëÇÏ¿© ü³»¿¡ µé¾î¿Â ¿ä¿Àµå°¡ ´Éµ¿¿î¹Ý¿¡ ÀÇÇØ °©»ó»ù¼¼Æ÷³»·Î µé¾î°¡ ¼¼Æ÷³»¿¡ ÀÖ´Â ´Ü¹éÁúÀÎ °©»ó»ù ±Û·Îºí¸°°ú °áÇÕÇÏ¿© °©»ó»ùÈ£¸£¸óÀ¸·Î ÇÕ¼ºµÈ´Ù. ¿ä¿Àµå°¡ 3ºÐÀÚ °áÇÕÇÑ °ÍÀ» T3, 4ºÐÀÚ °áÇÕÇÑ °ÍÀ» T4¶ó ºÎ¸§. ºÐºñµÇ´Â °©»ó¼± È£¸£¸óÁß 90%ÀÌ»óÀÌ T4ÀÌ´Ù. Ç÷ÁßÀ¸·Î ºÐºñµÈ °©»ó»ùÈ£¸£¸óÀº Ç÷Áß ´Ü¹éÁú°ú °áÇÕÇϴµ¥ ´ëºÎºÐÀº Ƽ·Ð½Å°áÇÕ±Û·Îºí¸°°ú °áÇÕÇϸç ÀϺδ ¾ËºÎ¹Î°ú °áÇÕÇÑ´Ù. Àü¹ÝÀûÀÎ ´ë»çÀ²À» ÃËÁø½ÃŰ¸ç ¾î¸°ÀÌ¿¡¼´Â ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ƯÈ÷ ¾î¸°ÀÌ¿¡¼ ¸ô´Ü¹éÁú ÇÕ¼ºÀ» ÃËÁøÇÏ¸ç ³úÀÇ ¹ß´Þ¿¡ Áß¿äÇÑ ±â´ÉÀ» ÇÔÀ¸·Î½á, ¼±Ãµ¼º °©»ó»ùÀúÇÏÁõ(cretinism)À» Á¶±â ¹ß°ßÇÏ¿© Ä¡·áÇÏÁö ¸øÇϸé Á¤½ÅÁöü°¡ À¯¹ßµÈ´Ù. °©»ó»ù°ú´ÙÁõÀÇ Áõ»óÀº ü³» ´ë»ç°¡ Ç×ÁøµÇ¾î ½Ä¿åÀÌ Áõ°¡Çϳª üÁßÀÌ °¨¼ÒÇÏ°í ½ÉÀå¹Úµ¿¼ö°¡ Áõ°¡ÇÏ°í ´õÀ§¸¦ ÂüÁö ¸øÇϸç, °©»ó»ù±â´ÉÀúÇÏÁõÀÇ Áõ»óÀº À§¿Í ¹Ý´ë·Î ½Ä¿åÀÌ °¨¼ÒÇϰí üÁßÀÌ Áõ°¡ÇÏ¸ç ½ÉÀå¹Úµ¿¼ö°¡ °¨¼ÒÇϰí ÃßÀ§¸¦ ÂüÁö ¸øÇϸç ÇǺο¡ ´Ü¹éÁúÀÌ ÃàÀûµÇ¾î Á¡¾×ºÎÁ¾ÀÌ À¯¹ßµÈ´Ù. |
||
| ¿µ¹® | adrenocorticotropic hormone | ÇÑ±Û | ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ³úÇϼöü Àü¿±¿¡¼ ºÐºñµÇ¾î ºÎ½Å°ÑÁúÀ» ÀÚ±ØÇÏ´Â ´Ü¹é¼º È£¸£¸ó. ÇϼöüÀü¿°¿¡¼ ¸¸µé¾îÁ® ºÐºñµÇ´Â È£¸£¸óÀÌ´Ù. ºÎ½Å°ÑÁúÀÚ±Ø ÀÛ¿ëÀÌ ÀÖÀ¸¸ç ºÎ½Å°ÑÁúÁú¼¼Æ÷ÀÇ °æ¿ì¿¡ ½ºÅ×·ÎÀ̵åÈ£¸£¸ó »ýÇÕ¼ºÀÇ Á¶Àý´Ü°èÀÎ ÄÝ·¹½ºÅ׷ѷκÎÅÍÀÇ ÇÁ·¹±×³×·Ñ·Ð»ý¼ºÀ» ÃËÁøÇÑ´Ù. °áÁ¤±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵忡 ÀÇÇØ ¹Ý´ëÀÇ µÇ¸ÔÀÓÁ¶Á¤À» ¹Þ´Â´Ù. ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵åÀÇ ÇϼöüÀü¿±¿¡ ´ëÇÑ Á÷Á¢ÀÛ¿ë°ú ½Ã»óÇϺÎÀÇ ºÎ½Å°ÑÁúÀÚ±ØÈ£¸£¸ó ¹æÃâÈ£¸£¸óÀ» ¸Åü·Î ÇÑ °£Á¢ÀÛ¿ëÀÌ ÀÖ´Ù. ¿©·¯ Á¾·ùÀÇ Á¤½ÅÀû À°Ã¼Àû ½ºÆ®·¹½º¿¡ ÀÇÇØ ºÐºñ°¡ ÀڱصȴÙ. |
||
| ¿µ¹® | growth hormone | ÇÑ±Û | ¼ºÀåÈ£¸£¸ó |
|---|---|---|---|
| ¼³¸í | ³úÇϼöü Àü¿±¿¡¼ ºÐºñµÇ´Â È£¸£¸óÁß Çϳª·Î¼ ½Ã»óÇϺÎÀÇ ¼ºÀåÈ£¸£¸ó¹æÃâ È£¸£¸ó¿¡ ÀÇÇØ ºÐºñ°¡ ÀÚ±ØµÇ¸ç ¼Ò¸¶Å佺Ÿƾ(somatostatin: ÀÌÀÚ¿¡¼ ºÐºñµÇ¸ç, ¼ºÀåÈ£¸£¸ó¿¡ ¹Ý´ëµÇ´Â ÀÛ¿ëÀ» ÇÔ)¿¡ ÀÇÇØ ºÐºñ°¡ ¾ïÁ¦µÈ´Ù. ¼ºÀå È£¸£¸ó ¹æÃâ È£¸£¸óÀº µµÆÄ¹Î(dopamine)À¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ¼ºÀå È£¸£¸óÀº ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½Ã۸ç ƯÈ÷ °ñÀÇ ¼ºÀåÀ» ÀÚ±ØÇϴµ¥ ±× ÀÛ¿ëÀº Á÷Á¢ ¼¼Æ÷¿¡ ÀÛ¿ëÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó °£°ú ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ±×°÷¿¡¼ ¼Ò¸¶Åä¸ÞµòÀ» »ý¼ºÇϸç ÀÌ ¼Ò¸¶Åä¸ÞµòÀÌ ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÃËÁø½ÃŲ´Ù. ÇÑÆí ¼ºÀå È£¸£¸óÀº ¼ºÀå¿¡ ÇÊ¿äÇÑ ´Ü¹éÁú ÇÕ¼ºÀ» Ç×Áø½ÃŰ°í ¿¡³ÊÁö´Â Áö¹æÀ» ÀÌ¿ëÇÏ¿© ¾ò°ÔÇϹǷΠÁö¹æÀÌ¿ëÈ£¸£¸óÀ̶ó°íµµ ºÒ¸°´Ù. ¼ºÀå È£¸£¸óÀÌ °ú´Ù ºÐºñµÇ¸é °ÅÀÎÁõ, ¸»´Üºñ´ëÁõÀÌ À¯¹ßµÇ¸ç ¼ºÀå È£¸£¸óÀÌ °áÇÌµÇ¸é ¼ºÀåºÎÁøÀÌ ¿Â´Ù. |
||
| MD | Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major... |
|---|---|
| IGD | idiopathic growth hormone deficiency; interglobal distance; isolated gonadotropin deficiency |
| LHRH | Luteinizing Hormone Releasing Hormone ? GnRH; Gonadotropin Releasing Hormone &nbs... |
| FSH/LR-RH | follicle-stimulating hormone and luteinizing hormone releasing hormone |
| MCD | magnetic circular dichroism; mast-cell degranulation; mean cell diameter; mean of consecutive differ... |
| CPHD | Combined pituitary hormone deficiency |
|---|---|
| GHD | Growth Hormone Deficiency |
| IGHD | Isolated Growth Hormone Deficiency |
| MPHD | Multiple Pituitary Hormone Deficiency |
| IGHD | idiopathic growth hormone deficiency |
| receptors, pituitary hormone-regulating hormone | Cell surface receptors that bind the hypothalamic hormones regulating pituitary cell differentiation, proliferation, and hormone synthesis and release, including the pituitary-releasing and release-inhibiting hormones. The pituitary hormone-regulating hormones are also released by cells other than hypothalamic neurons, and their receptors also occur on non-pituitary cells, especially brain neurons, where their role is less well understood. Receptors for dopamine, which is a prolactin release-inhibiting hormone as well as a common neurotransmitter, are not included here. (12 Dec 1998) |
|---|---|
| growth hormone inhibiting hormone | <protein> Gastrointestinal and hypothalmic peptide hormone (two forms: 14 and 28 residues), found in gastric mucosa, pancreatic islets, nerves of the gastrointestinal tract, in posterior pituitary and in the central nervous system. Inhibits gastric secretion and motility: in hypothalamus/pituitary inhibits somatotropin release. (18 Nov 1997) |
| growth hormone-regulating hormone | <endocrinology> Hypothalamic hormones that induce (somatoliberin) or inhibit (somatostatin) the release of growth hormone (somatotropin). (18 Nov 1997) |
| growth hormone-releasing hormone | <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone. Synonym: somatoliberin, growth hormone-releasing factor. (20 Sep 2002) |
| hormones, hormone substitutes, and hormone antagonists | A collective grouping for both naturally occurring and synthetic hormones, substitutes, and antagonists. (12 Dec 1998) |
| follicle-stimulating hormone-releasing hormone | A decapeptide of hypothalamic origin capable of accelerating pituitary secretion of follitropin. Synonym: follicle-stimulating hormone-releasing factor, follicle-stimulating hormone-releasing hormone. Origin: follicle-stimulating hormone + L. Libero, to free, + -in (05 Mar 2000) |
| luteinizing hormone/follicle-stimulating hormone-releasing factor | gonadotrophin-releasing hormone |
| luteinizing hormone-releasing hormone | A hormone that controls sex hormones in men and women. Also called lhrh. (12 Dec 1998) |
| abdominal muscle deficiency syndrome | <syndrome> Congenital absence (partial or complete) of abdominal muscles, in which the outline of the intestines is visible through the protruding abdominal wall; in males, genitourinary anomalies (urinary tract dilation and cryptorchidism) are also found; genetics unclear. (05 Mar 2000) |
| adult lactase deficiency | Onset of lactase deficiency, with resulting milk intolerance and malabsorption, in adulthood. Inherited forms may not be manifested until adulthood; any process that damages the intestinal lining cells can cause lactase deficiency in adults. (05 Mar 2000) |
| alpha-1 antitrypsin deficiency | <chest medicine> Deficiency of the protease inhibitor alpha-1 antitrypsin, leads primarily to degradation of elastin of the alveolar walls, as well as other structural proteins of a variety of tissues. The lack of this protein leads to damage of various organs, but mainly to the lung and liver. symptoms may become apparent at a very early age or in adulthood, manifesting either as shortness of breath or liver related symptoms (jaundice, fatigue, fluid in the abdomen, mental changes, or gastrointestinal bleeding). There are several options for treatment of the lung disease, including replacement of the missing protein. Treatment of the liver disease is a well-timed liver transplant (12 Dec 1998) |
| alpha-1-proteinase deficiency | Absence of a serum proteinase inhibitor that may cause nodular non-suppurative panniculitis. (05 Mar 2000) |
| alpha-antitrypsin deficiency | <enzyme> A specific enzyme (alpha 1 antitrypsinase) that when absent genetically can result in panacinar emphysema (lung disease) and liver disease. There is no specific treatment for this condition other than supportive care for the liver and lung complications. Medications such as alpha-1proteinase inhibitor is given regularly to these patients. Incidence: approximately 1 in 10,000. (02 Jan 1998) |
| anaemia, iron deficiency | Deficiency of iron results in anaemia because iron is necessary to make haemoglobin, the key molecule in red blood cells responsible for the transport of oxygen. In iron deficiency anaemia, the red cells are unusally small (microcytic) and pale (hypochromic). Characteristic features of iron deficiency anaemia in children include failure to thrive (grow) and increased infections. The treatment of iron deficiency anaemia, whether it be in children or adults, is with iron and iron-containing foods. Food sources of iron include meat, poultry, eggs, vegetables and cereals (especially those fortified with iron). According to the National Academy of Sciences, the Recommended Dietary Allowances of iron are 15 milligrams per day for women and 10 milligrams per day for men. Anaemia characterised by low or absent iron stores, low serum iron concentration, elevated free erythrocyte porphorin, low transferrin saturation, elevated transferrin, low serum ferritin, low haemoglobin concentration or haematocrit, and hypochromic microcytic red blood cells. Symptoms may include pallor, angular stomatitis and other oral lesions, gastrointestinal complaints, retinal haemorrhages and exudates, and thinning and brittleness of the nails. Among the causes of iron-deficiency anaemia are inadequate iron intake, impaired iron absorption, increased blood loss and increased requirements such as infancy, pregnancy, and lactation. (12 Dec 1998) |
| antibody deficiency disease | <syndrome> Any of a group of disorders associated with a defective antibody production due to defects in the B-type lymphocyte system or in T-type lymphocytes; chief manifestation is an increased susceptibility to infection by various microorganisms. See: agammaglobulinaemia, hypogammaglobulinaemia, immunodeficiency. Synonym: antibody deficiency disease. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|